Notes

Paediatric assistive hearing device make use of: a systematic review.
k pain.
Studies analyzing morphometry of neck extensor musculature have mostly used Magnetic Resonance Imaging (MRI). Panoramic Ultrasound View could be used for obtaining high-quality 2D cross-sectional images with a wide field of view more cost-effectively imaging acquisition by creating an automatic construction of 2D cross-sectional images.

To measure neck extensors cross-sectional area (CSA) using panoramic ultrasound view in healthy subjects.

Cross-sectional study.

Panoramic B-mode ultrasound images of the neck extensor muscles at C4/C5 level were acquired in 25 healthy subjects (40% women, mean age 24±5 years) by an experienced assessor. The CSA of the upper trapezius, splenius (layer), semispinalis (layer), multifidi, short rotators, and levator scapulae were calculated. The relative percentage in the total neck extensor muscle volume of each CSA was also determined. Sex and side-to-side comparisons were conducted.

Men showed larger CSAs than women in all muscles (all, P<0.01). No side-to-side differences were found in either men or women (all, P>0.05). Significant positive associations between CSA with weight (r 0.654 to 0.375, P<0.01), height (r 0.386 to 0.581, P<0.05), and BMI (r 0.369 to 0.563, P<0.05) were found. Men showed greater percentage of upper trapezius and semispinalis muscle layers than women (P<0.01), whereas women had a greater percentage of levator scapulae muscle than men (P<0.01) from the total volume of the neck extensors. No side-to-side differences were found either.

The current study describes CSA, as assessed with panoramic ultrasound view, of the neck extensors in healthy people. Men exhibited greater CSA than women with no side-to-side differences.
The current study describes CSA, as assessed with panoramic ultrasound view, of the neck extensors in healthy people. Men exhibited greater CSA than women with no side-to-side differences.
Solitary fibrous tumor / hemangiopericytoma (SFT/HPC) has a similar radiographic appearance to angiomatous meningioma (AM). However, not like angiomatous meningioma with benign outcome, SFT/HPC tend to exhibit aggressive behavior. Distinguishing them preoperatively is important for determining the treatment and follow-up plan.The aim of this study was to determine the clinical and radiographic factors that can be used to differentiate SFT/HPC from AM.

The analysis included 57 cases of SFT/ HPC and 64 cases of angiomatous meningioma. Clinical characteristics and conventional magnetic resonance imaging were evaluated via multivariate logistic regression analysis using IBM SPSS to identify the factors that distinguish SFT/HPC from angiomatous meningioma.

Patients with SFT/HPC were younger than those with angiomatous meningioma (mean age 47.4 years VS 54.8 years, P = 0.001). The mean maximum diameter of SFTs/ HPCs was larger than that of angiomatous meningiomas (4.9 cm VS 3.5 cm, p < 0.001). Angiomatous meningiomas were more likely with dural tail sign (p < 0.001) and serious peritumoral edema (p < 0.001) compared with SFTs/HPCs. Tumor with signal value difference between white matter and tumor parenchyma in T1- weighted images between -20 to 100 or in T2- weighted images between -220 to 20 may be, with high probability, a SFT/ HPC instead of a AM.

Age, tumor size, dural tail sign, peritumoral edema, signal value difference between white matter and tumor parenchyma in T1- and T2- weighted images may help distinguishing SFT/HPC from angiomatous meningioma preoperatively.
Age, tumor size, dural tail sign, peritumoral edema, signal value difference between white matter and tumor parenchyma in T1- and T2- weighted images may help distinguishing SFT/HPC from angiomatous meningioma preoperatively.SARS-CoV-2 mainly invades respiratory epithelial cells by adhesion to angiotensin-converting enzyme 2 (ACE-2) and thus, infected patients may develop mild to severe inflammatory responses and acute lung injury. Afferent impulses that result from the stimulation of pulmonary mechano-chemoreceptors, peripheral and central chemoreceptors by inflammatory cytokines are conducted to the brainstem. Integration and processing of these input signals occur within the central nervous system, especially in the limbic system and sensorimotor cortex, and importantly feedback regulation exists between O2, CO2, and blood pH. Despite the intensity of hypoxemia in COVID-19, the intensity of dyspnea sensation is inappropriate to the degree of hypoxemia in some patients (silent hypoxemia). We hypothesize that SARS-CoV-2 may cause neuronal damage in the corticolimbic network and subsequently alter the perception of dyspnea and the control of respiration. SARS-CoV-2 neuronal infection may change the secretion of numerous endogenous neuropeptides or neurotransmitters that distribute through large areas of the nervous system to produce cellular and perceptual effects. SARS-CoV-2 mainly enter to CNS via direct (neuronal and hematologic route) and indirect route. We theorize that SARS-CoV-2 infection-induced neuronal cell damage and may change the balance of endogenous neuropeptides or neurotransmitters that distribute through large areas of the nervous system to produce cellular and perceptual effects. Thus, SARS-CoV-2-associated neuronal damage may influence the control of respiration by interacting in neuromodulation. This would open up possible lines of study for the progress in the central mechanism of COVID-19-induced hypoxia. Future research is desirable to confirm or disprove such a hypothesis.
Cervical spondylotic myelopathy (CSM) is a major cause of cervical spinal cord dysfunction in people over 55 years of age. Most patients with CSM usually present with chronic and phased compression, however, some patients with CSM develop rapid severe neurological dysfunction without any trauma. To our knowledge, markers that can be used for early identification of patients with potential to develop rapid neurological deterioration have not been totally identified. Here, we evaluate epidemiological, clinical and radiographic features associated with the development and prognosis of rapid progressive cervical spondylotic myelopathy (rp-CSM).

A retrospective study was carried out for 175 patients diagnosed with CSM between March 2011 and January 2017 at West China Hospital. Patients were divided into rp-CSM group and chronic CSM (c-CSM) group based on the time taken for neurological deterioration to occur and the severity of preoperative neurological dysfunction. The clinical outcomes were assessed using thioration can be identified by TPR MRI ( less then 0.4), compression ratio (≥50 %), sagittal diameter of ISI (≥50 % of spinal canal diameter). Besides, a history of diabetes is a risk factor for the development of rp-CSM.This study aimed to optimize a new sample preparation method using N-doped mesoporous carbon sorbent for simultaneous measurement of 1-naphthol and 2-naphthol, the biomarkers of exposure to naphthalene. The samples were analyzed using high-performance liquid chromatography supplied with ultraviolet detector (HPLC-UV). N-doped mesoporous carbon sorbent was obtained via the hard template procedure. The synthesized nanosorbent was then characterized by transmission electron microscopy (TEM), Brunauer-Emmett-Teller (BET), and elemental analysis (CHN). The effective factors in the extraction of the studied biomarkers were examined by the Box-Behnken (BBD) methodology. Regarding the optimum conditions, the sketched calibration curve for naphthols was linear in the concentration levels of 1-600 µg L-1 for human urine samples. The accuracy and reproducibility of the introduced method were determined using the relative recovery (RR %) and relative standard deviation (RSD %) tests on the fortified urine samples. RR% and RSD% were found to be 97.0-101.2% and 3.1-9.0%, respectively. The calculated method detection limit of the optimized procedure was 0.3 µg L-1 and 0.5 µg L-1 for 1-naphthol and 2-naphthol, respectively.Dexmedetomidine, as a safe sedative, mainly exerts on the central nervous system particularly in the locus coeruleus producing arousable sedation with potential analgesic and anxiolytic effects. The quantification and pharmacokinetic investigation of dexmedetomidine in the central nervous system have been described rarely. In order to estimate the unbound dexmedetomidine concentrations in brain extracellular fluid and blood simultaneously, we employed microdialysis technique as a sampling method and primarily established a rapid, sensitive and selective high-performance liquid chromatography coupled with tandem mass spectrometry method (HPLC-MS/MS). Dexmedetomidine and the internal standard (dexmedetomidine-d4) were extracted in liquid-liquid extraction procedure with ethyl acetate from 10 μL of alkalinized microdialysate sample. After evaporation under nitrogen at room temperature, the analytes were reconstituted in acetonitrile and transferred to be detected. HPLC was performed on an Agilent Poroshell 120 Hilic column (4.6 × 100 mm, 2.7 μm) with isocratic elution at a flow rate of 0.3 mL/min by 0.1% formic acid/acetonitrile (6040, v/v). The detection was performed on a triple quadrupole tandem mass spectrometer in the multiple reaction monitoring (MRM) mode using the respective [M+H]+ ions m/z 201.2 to m/z 95.1 for DEX and m/z 205.2 to m/z 99.1 for IS (DEX-d4). The concentration-response relationship was of good linearity over a concentration range of 1.00-1000.00 ng/mL with the correlation coefficient above 0.999. The lower limit of quantification was 1.00 ng/mL with a relative standard deviation of less than 20%. The intra- and inter-day accuracy were within ±5.00% and precision was less then 7.23%. The recoveries of dexmedetomidine in microdialysates were 76.61-93.38%. The validated HPLC-MS/MS method has been successfully applied to study the pharmacokinetics of dexmedetomidine in rats after a caudal vein administration.As an anticoagulant, Edoxaban (EDX) is a high risk drug that may cause a life-threatening bleeding. Also, it is prescribed as a chronic therapy for atrial fibrillation and venous thromboembolism patients. They are special population that needs appropriate care and optimum dosing of EDX. Hence, its monitoring in the patient plasma is fundamental, especially in emergency and special circumstances. However, such patient mostly receives many drugs of different pharmacological classes, side by side with EDX. This study represents the first attempt to quantify EDX in plasma without interference of the plasma matrix or concomitant medications. An accurate RP-HPLC-DAD method was developed for this purpose. It succeeded to monitor EDX level, selectively, without interference of plasma matrix or 16 of its frequently co-administered drugs. All drugs were extracted from plasma samples by protein precipitation followed by evaporation and concentration. EDX was well resolved from the co-administered drugs on C8 column using linear gradient elution of methanol and phosphate buffer (pH 4), at a flow rate of 1 mL/min. EDX appeared at retention time 9.6 min and was quantified at its λmax (290 nm). It exhibited a linear response over the concentration range of 0.15-2.2 μg/mL plasma which covers the reported therapeutic concentration. The suggested method fulfilled the US FDA guidelines for bioanalytical method validation. The developed method is fully discussed in comparison with the reported techniques. An in vivo study was performed to ensure applicability of the method on real plasma samples without interference from plasma matrix, co-administered drugs or the expected metabolites. It presented a unique selectivity of the method that guarantees accurate laboratory monitoring of EDX in plasma in almost all combined treatments including such novel oral anticoagulant drug.
Website: